Differential effects of rolipram on chronic subcutaneous inflammatory angiogenesis and on peritoneal adhesion in mice

Microvascular Research

Volumn 78, Issue 3, 2009, Pages 265-271

  Mendes, Juliana B ^a   Rocha, Monaliza A ^a   Araújo, Fernanda A ^a   Moura, Sandra A L ^a   Ferreira, Mônica A N D ^a   Andrade, Silvia Passos ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Collagen; Cytokines; Phosphodiesterase inhibitor; Sponge implants

Indexed keywords

ACETYLGLUCOSAMINIDASE; COLLAGEN; CYCLIC NUCLEOTIDE; CYTOKINE; HEMOGLOBIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; PHOSPHODIESTERASE IV INHIBITOR; POLYETHER; POLYURETHAN; ROLIPRAM; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; EXPERIMENTAL MODEL; EXTRACELLULAR MATRIX; FIBROBLAST; INFLAMMATORY CELL; INHIBITION KINETICS; MACROPHAGE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PERITONEUM ADHESION; PRIORITY JOURNAL; TREATMENT DURATION;

ADMINISTRATION, ORAL; ANIMALS; CHEMOKINE CCL2; COLLAGEN; DISEASE MODELS, ANIMAL; FIBROSIS; INFLAMMATION; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; NEUTROPHILS; PERITONEUM; PHOSPHODIESTERASE INHIBITORS; ROLIPRAM; SURGICAL SPONGES; TISSUE ADHESIONS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MURINAE; MUS;

EID: 71549116728     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2009.08.008     Document Type: Article

References (30)

1. Ariga M., Neitzert B., Nakae S., Mottin G., Bertrant C., Pruniaux M.P., Jin S.-L.C., and Conti M. Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J. Immunol. 173 (2004) 7531-7538
2. Armstrong R.A.. Investigation of the inhibitory effects of PGE2 and selective EP agonists on chemotaxis of human neutrophils. Br. J. Pharmacol. 116 7 (1995) 2903-2908
3. Barcelos L.S., Coelho A.M., Russo R.C., Guabiraba R., Souza A.L., Bruno-Lima Jr. G., Proudfoot A.E., Andrade S.P., and Teixeira M.M. Role of the chemokines CCL3/MIP-1alpha and CCL5/RANTES in sponge-induced inflammatory angiogenesis in mice. Microvasc. Res. (2009) 78 (2), 148-154
4. Campos P.P., Bakhle Y.S., and Andrade S.P. Mechanisms of wound healing responses in lupus-prone New Zealand White mouse strain. Wound Rep. Reg. 16 (2008) 416-424
5. Cheong Y.C., Laird S.M., Li T.C., Shelton J.B., Ledger W.L., and Cooke I.D. Peritoneal healing and adhesion formation/reformation. Hum. Reprod. Update 7 6 (2001) 556-566
6. Corbel M., Germain N., Lanchou J., Molet S., R e Silva P.M., Martins M.A., Boichot E., and Lagente V. The selective phosphodiesterase 4 inhibitor RP 73-401 reduced matrix metalloproteinase 9 activity and transforming growth factor-beta release during acute lung injury in mice: the role of the balance between tumor necrosis factor-alpha and interleukin-10. J. Pharmacol. Exp. Ther. 301 1 (2002) 258-265
7. Epstein J.C., Wilson M.S., Wilkosz S., Ireland G., O'Dwyer S.T., and Herrick S.E. Human peritoneal adhesions show evidence of tissue remodeling and markers of angiogenesis. Dis. Colon Rectum 49 12 (2006) 1885-1892
8. Favot L., Keravis T., Holl V., Le Bec A., and Lugnier C. VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb. Haemost. 90 2 (2003) 334-343
9. Gude R.P., Binda M.M., Boquete A.L., and Bonfil R.D. Inhibition of endothelial cell proliferation and tumor-induced angiogenesis by pentoxifylline. J. Cancer Res. Clin. Oncol. 127 10 (2001) 625-630
10. Harada D., Takada C., Nosaka Y., Takashima Y., Kobayashi K., Takaba K., and Manabe H. Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models. Int. Immunopharmacol. 9 1 (2009) 55-62
11. Hasebe Y., Thomson L.R., and Dorey C.K. Pentoxifylline inhibition of vasculogenesis in the neonatal rat retina. Invest. Ophthalmol. Vis. Sci. 41 9 (2000) 2774-2778
12. Hashimoto A., Miyakoda G., Hirose Y., and Mori T. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 189 2 (2006) 350-357
13. Kohyama T., Liu X., Wen F.Q., Zhu Y.K., Wang H., Kim H.J., Takizawa H., Cieslinski L.B., Barnette M.S., and Rennard S.I. PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am. J. Respir. Cell Mol. Biol. 26 6 (2002) 694-701
14. Lage A.P., and Andrade S.P. Assessment of angiogenesis and tumor growth in conscious mice by a fluorimetric method. Microvasc. Res. 59 2 (2000) 278-285
15. Lagente V., Pruniaux M.P., Junien J.L., and Moodley I. Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors. Am. J. Respir. Crit. Care Med. 151 (1995) 1720-1724
16. Lagente V., Martin-Chouly C., Boichot E., Martins M.A., and Silva P.M. Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases. Mem. Inst. Oswaldo Cruz 100 Suppl. 1 (2005) 131-136
17. Martin-Chouly C.A., Astier A., Jacob C., Pruniaux M.P., Bertrand C., and Lagente V. Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors. Life Sci. 75 7 (2004) 823-840
18. Mendes J.B., Campos P.P., Ferreira M.A., Bakhle Y.S., and Andrade S.P. Host response to sponge implants differs between subcutaneous and intraperitoneal sites in mice. J. Biomed. Mat. Res. Part B, Applied Biomaterials 83 2 (2007) 408-415
19. Mendes J.B., Campos P.P., Rocha M.A., and Andrade S.P. Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice. Life Sci. 84 15-16 (2009) 537-543
20. Menzies D., and Ellis H. Intestinal obstruction from adhesions-how big is the problem?. Ann R. Coll. Surg. Engl. 72 1 (1990) 60-63
21. Moore A.R., and Willoughby D.A. The role of cAMP regulation in controlling inflammation. Clin. Exp. Immunol. 101 3 (1995) 387-389
22. Netherton S.J., and Maurice D.H. Vascular endothelial cell cyclic nucleotide phosphodiesterase and regulated cell migration: implications in angiogenesis. Mol. Pharmacol. 67 (2005) 263-272
23. Nishio Y., Kashiwagi A., Takahara N., Hidaka H., and Kikkawa R. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells. Horm. Metab. Res. 29 10 (1997) 491-495
24. Odashima M., Otaka M., Jin M., Komatsu K., Konishi N., Wada I., Horikawa Y., Matsuhashi T., Ohba R., Oyake J., Hatakeyama N., and Watanabe S. Rolipram, a specific type IV phosphodiesterase inhibitor, ameliorates aspirin-induced gastric mucosal injury in rats. Dig. Dis. Sci. 50 6 (2005) 1097-1102
25. Podolsky D.K. The current future understanding of inflammatory bowel disease. Best Pract. Res. Clin. Gastroenterol. 16 6 (2002) 933-943
26. 1 activity, and amelioration of collagen-induced arthritis by rolipram. J. Immunol. 159 12 (1997) 6253-6259
27. Schudt C., Tenor H., and Hatzelmann A. PDE isoenzymes as targets for anti-asthma drugs. Eur. Respir. J. 8 7 (1995) 1179-1183
28. Teixeira M.M., Gristwood R.W., Cooper N., and Hellewell P.G. Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?. Trend Pharmacol. Sci. 18 (1997) 164-170
29. Toward T.J., and Broadley K.J. Airway function, oedema, cell infiltration and nitric oxide generation in conscious ozone-exposed guinea-pigs: effects of dexamethasone and rolipram. Br. J. Pharmacol. 136 5 (2002) 735-745
30. Videla S., Vilaseca J., Medina C., Mourelle M., Guarner F., Salas A., and Malagelada J.R. Modulatory effect of nitric oxide on mast cells during induction of dextran sulfate sodium colitis. Dig. Dis. Sci. 52 1 (2006) 45-51